how many different crypto should i own, People searches

South Korea's exports increased by 12.4% and imports increased by 11.6% from December 1 to 10. South Korea's chip exports increased by 43% year-on-year from December 1 to 10.Nikkei futures opened down 95 points at 39,290 on the Singapore Stock Exchange.Lian Ping, president of the Chief Industry Research Institute of Guangkai, believes that it is expected to reduce the RRR by about 100 basis points in 2025, releasing more than 3 trillion yuan of liquidity. Among them, there is limited room for reducing the deposit reserve ratio of small and medium-sized financial institutions, and the expected RRR reduction is about 50 basis points.

Sarah Friar, CFO of OpenAI: Corporate customers will pay (at least) thousands of dollars for using artificial intelligence (AI) tools. In the end, it will be reasonable.Japan's producer price in November increased by 0.3% month-on-month, and it is estimated to increase by 0.2%. Japan's producer price in November increased by 3.7% year-on-year, and it is estimated to increase by 3.4%.China Huaneng and Huawei signed a strategic cooperation agreement. On December 6th, China Huaneng Group Co., Ltd. (hereinafter referred to as "Huaneng") and Huawei Technologies Co., Ltd. (hereinafter referred to as "Huawei") signed a strategic cooperation agreement. Wen Shugang, Chairman and Party Secretary of Huaneng Group, held talks and witnessed the signing of the contract with Meng Wanzhou, rotating chairman and CFO of Huawei, and jointly unveiled Huaneng-Huawei New Energy joint innovation lab. According to the agreement, the two sides will continue to deepen strategic cooperation in the fields of clean energy cooperation, digital transformation cooperation, the establishment of joint innovation lab, and corporate culture exchange.

Ministry of Finance of the Republic of Korea: We will pay close attention to the financial and foreign exchange market trends and take adequate measures to curb excessive fluctuations in the foreign exchange market.Galaxy Securities: It is recommended to pay attention to the upgrading of network infrastructure, telecom operators, optical module leaders, quantum communication leaders, Internet of Things and cutting-edge applications, etc. china galaxy Securities said that the demand for communication equipment as the base of computing infrastructure in the digital economy is expected to usher in high growth, and related sectors may usher in greater opportunities, focusing on emerging industries such as operators, optical communications, quantum communications and 5G applications to empower related industrial chains. It is suggested to pay attention to: network infrastructure upgrade+telecom operators, optical module leaders, quantum communication leaders, Internet of Things and cutting-edge applications led by central enterprises.Guotai Junan's annual strategy for innovative drugs in 2025: innovative pharmaceutical companies have accelerated into the harvest period, and the valuation has been at a historical low in the past five years. Guotai Junan said that the centralized purchasing policy has become stable, mature and normalized, and the marginal impact has weakened. Innovative drugs have gained policy inclination in the medical insurance negotiation. In the past two years, the policy has continued to promote pharmaceutical innovation, and the top-level design and local supporting chain support the development of innovative drugs. Commercial insurance is expected to bring new growth momentum to China's pharmaceutical market, and the overall industry trend is upward. At present, the trend of innovative drug industry is improving, the supply continues to accelerate, and a number of domestic innovative drugs are approved soon, which is expected to drive a new round of heavy volume. At the same time, the commercialization has achieved remarkable results and has occupied a dominant position in some sub-sectors. Pharma's performance continued to differentiate, and innovative drugs and just-needed drugs performed well. Biotech commercialization continues to increase, per capita yield continues to increase, the node of turning losses is approaching, and innovation ushers in the harvest period. Horizontal comparison: compared with overseas peers, the overall valuation of domestic innovative pharmaceutical companies is in a historically low range; Vertical comparison: the valuation of SW- pharmaceutical biology and SW- chemical preparations is at a historical low in the past five years, and it is expected that the valuation of subsequent sectors will pick up.